InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 280159

Friday, 12/02/2016 8:06:50 PM

Friday, December 02, 2016 8:06:50 PM

Post# of 345681
Reduction in MDSCs (PS Targeting MOA) in cancers leads to overall survival ....looks like Dec 7 is a popular date to talk about how one must decrease MDSCs

Nice that Peregrines MOA in PS Targeting does just that and things suddenly become very intriguing around these parts

Prof. Vincenzo Bronte Head of Department of Immunology Faculty of Medicine University of Verona Italy

http://ispb.univ-lyon1.fr/la-faculte/actualites/conference-myeloid-derived-suppressor-cells-in-cancers-7th-of-december-15h00-salle-mediatheque-paul-zech-868708.kjsp

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News